Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 5
2003 10
2004 15
2005 18
2006 13
2007 16
2008 12
2009 11
2010 3
2011 7
2012 8
2013 13
2014 15
2015 9
2016 7
2017 9
2018 9
2019 10
2020 6
2021 10
2022 8
2023 11
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

213 results

Results by year

Filters applied: . Clear all
Page 1
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder.
Yamamura T, Kleiter I, Fujihara K, Palace J, Greenberg B, Zakrzewska-Pniewska B, Patti F, Tsai CP, Saiz A, Yamazaki H, Kawata Y, Wright P, De Seze J. Yamamura T, et al. N Engl J Med. 2019 Nov 28;381(22):2114-2124. doi: 10.1056/NEJMoa1901747. N Engl J Med. 2019. PMID: 31774956 Clinical Trial.
Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.
Traboulsee A, Greenberg BM, Bennett JL, Szczechowski L, Fox E, Shkrobot S, Yamamura T, Terada Y, Kawata Y, Wright P, Gianella-Borradori A, Garren H, Weinshenker BG. Traboulsee A, et al. Among authors: yamamura t. Lancet Neurol. 2020 May;19(5):402-412. doi: 10.1016/S1474-4422(20)30078-8. Lancet Neurol. 2020. PMID: 32333898 Free PMC article. Clinical Trial.
Long-term Efficacy of Satralizumab in AQP4-IgG-Seropositive Neuromyelitis Optica Spectrum Disorder From SAkuraSky and SAkuraStar.
Kleiter I, Traboulsee A, Palace J, Yamamura T, Fujihara K, Saiz A, Javed A, Mayes D, Büdingen HV, Klingelschmitt G, Stokmaier D, Bennett JL. Kleiter I, et al. Among authors: yamamura t. Neurol Neuroimmunol Neuroinflamm. 2022 Dec 8;10(1):e200071. doi: 10.1212/NXI.0000000000200071. Print 2023 Jan. Neurol Neuroimmunol Neuroinflamm. 2022. PMID: 36724181 Free PMC article. Clinical Trial.
Editorial: Neuroimmunology.
Yamamura T. Yamamura T. Neurochem Int. 2019 Nov;130:104517. doi: 10.1016/j.neuint.2019.104517. Epub 2019 Aug 1. Neurochem Int. 2019. PMID: 31377135 No abstract available.
Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology.
Fujihara K, Bennett JL, de Seze J, Haramura M, Kleiter I, Weinshenker BG, Kang D, Mughal T, Yamamura T. Fujihara K, et al. Among authors: yamamura t. Neurol Neuroimmunol Neuroinflamm. 2020 Aug 20;7(5):e841. doi: 10.1212/NXI.0000000000000841. Print 2020 Sep 3. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 32820020 Free PMC article. Review.
Plasmablasts and neuroimmunological disorders.
Chihara N, Matsumoto R, Yamamura T. Chihara N, et al. Among authors: yamamura t. Immunol Med. 2019 Sep;42(3):103-107. doi: 10.1080/25785826.2019.1659476. Epub 2019 Aug 29. Immunol Med. 2019. PMID: 31464170 Review.
Gut environmental factors and multiple sclerosis.
Miyake S, Yamamura T. Miyake S, et al. Among authors: yamamura t. J Neuroimmunol. 2019 Apr 15;329:20-23. doi: 10.1016/j.jneuroim.2018.07.015. Epub 2018 Jul 27. J Neuroimmunol. 2019. PMID: 30077395 Review.
Gut microbiome research in multiple sclerosis.
Takewaki D, Yamamura T. Takewaki D, et al. Among authors: yamamura t. Neurosci Res. 2021 Jul;168:28-31. doi: 10.1016/j.neures.2021.05.001. Epub 2021 May 11. Neurosci Res. 2021. PMID: 33989681 Review.
213 results